10x Genomics Q4 revenue down 10% YoY to $165M; FY2024 net loss $182.6M; guidance ~flat

10x Genomics, Inc.

2024-FY EPS reported -$1.52 revenue$610,785,000

Q4 2024 revenue $165.0M (-10% YoY); full year $610.8M (-1% YoY).
Q4 operating loss $49.8M, net loss $49.0M (unchanged YoY).
Full year 2024 net loss $182.6M, improved from $255.1M loss in 2023.
FY2025 revenue guidance $610M-$630M (0-3% growth); midpoint implies double-digit growth for Chromium and spatial.
Cash and securities $393.4M; launched Billion Cells Project with CZI and Ultima Genomics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.